Mutations and prognosis in primary myelofibrosis

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Patient outcomes in primary myelofibrosis (PMF) are significantly influenced by karyotype.
• Somatic mutations play a crucial role in disease progression and patient prognosis.

Purpose of the Study:

• To determine the individual and combinatorial prognostic relevance of somatic mutations in PMF.
• To validate findings across independent patient cohorts.

Main Methods:

• Analysis of 879 PMF patients (483 European, 396 Mayo Clinic).
• Somatic mutation profiling for ASXL1, SRSF2, EZH2, TET2, DNMT3A, CBL, IDH1, IDH2, MPL, and JAK2.
• Survival and leukemia-free survival analyses, incorporating IPSS and DIPSS-plus models.

Main Results:

• ASXL1, SRSF2, and EZH2 mutations independently predicted shortened survival in the European cohort.
• ASXL1 mutations remained a significant independent predictor of survival in both European (IPSS) and Mayo Clinic (DIPSS-plus) cohorts.
• Mutations in ASXL1, SRSF2, and IDH1/2 were associated with negative impacts on leukemia-free survival.

Conclusions:

• Mutational profiling, particularly for ASXL1, EZH2, SRSF2, and IDH, can identify PMF patients at high risk for premature death or leukemic transformation.
• These findings enhance prognostic models for primary myelofibrosis, guiding clinical management.